July 24 (Reuters) – Sanofi SA: * SANOFI ANNOUNCES DECISION NOT TO SUBMIT AMLITELIMAB IN ATOPIC DERMATITIS FOR GLOBAL REGULATORY REVIEWS * DISCONTINUES CLINICAL DEVELOPMENT OF AMLITELIMAB IN ATOPIC
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)